Millennium Management
FDMT icon

Millennium Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Millennium Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$1.11M – 6507
2022
Q4 		$1.11M Buy
+50,000
New +$772K ﹤0.01% 4058

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management's FDMT Position: Q1 2026 in Review

Millennium Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 96,364 shares — an estimated $723K sold.

Millennium Management first reported a position in FDMT in Q4 2020 and held it in 18 quarters. The position peaked at $14.5M in Q1 2021. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Millennium Management reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 96,364 4D Molecular Therapeutics shares in Q1 2026, an estimated $723K.
  • Millennium Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 18 quarters.
  • Millennium Management's 4D Molecular Therapeutics position peaked at $14.5M in Q1 2021.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.